LIVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LivaNova PLC (LIVN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and constructive financial health outweigh short-term challenges like declining net income. The technical indicators suggest bullish momentum, and the stock is trading close to analysts' price targets, making it a reasonable entry point for long-term growth.
The technical indicators for LIVN are bullish. The MACD histogram is positive at 0.369 and expanding, indicating upward momentum. The RSI_6 is at 83.08, signaling overbought conditions, but this is consistent with strong upward trends. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near resistance levels (R1: 71.021, R2: 73.148), suggesting potential for further upside.
Strong Q4 2025 revenue growth of 12.15% YoY, reaching $361 million.
Positive analyst sentiment with multiple price target increases (e.g., Stifel raised to $80, KeyBanc to $81).
Strategic focus on core business innovation and entry into the obstructive sleep apnea market.
Healthy cash balance of $636 million, supporting future growth initiatives.
Net income and EPS declined significantly in Q4 2025 (-44.70% and -44.12% YoY, respectively).
Gross margin dropped by 2.54% YoY, indicating some pressure on profitability.
Overbought RSI suggests potential short-term pullback.
In Q4 2025, LivaNova reported a 12.15% YoY increase in revenue to $361 million, showcasing strong top-line growth. However, net income dropped by 44.70% YoY to $30.91 million, and EPS decreased by 44.12% YoY to $0.57. Gross margin also declined slightly to 66.43%. Despite these challenges, the company maintains a robust cash position of $636 million, indicating financial stability.
Analyst sentiment is generally positive. Stifel raised the price target to $80 with a Buy rating, citing strong performance in neuromodulation and cardiopulmonary divisions. KeyBanc initiated coverage with an Overweight rating and an $81 price target, highlighting an 'underappreciated performance inflection.' Goldman Sachs and Barclays maintain Neutral and Equal Weight ratings, respectively, but have raised price targets to $73 and $67, reflecting improved growth expectations.
